title: Substrate and inhibitor specificity of Mycobacterium avium dihydrofolate reductase.
abstract: Dihydrofolate reductase (EC 1.5.1.3) is a key enzyme in the folate biosynthetic pathway. Information regarding key residues in the dihydrofolate-binding site of Mycobacterium avium dihydrofolate reductase is lacking. On the basis of previous information, Asp31 and Leu32 were selected as residues that are potentially important in interactions with dihydrofolate and antifolates (e.g. trimethoprim), respectively. Asp31 and Leu32 were modified by site-directed mutagenesis, giving the mutants D31A, D31E, D31Q, D31N and D31L, and L32A, L32F and L32D. Mutated proteins were expressed in Escherichia coli BL21(DE3)pLysS and purified using His-Bind resin; functionality was assessed in comparison with the recombinant wild type by a standard enzyme assay, and growth complementation and kinetic parameters were evaluated. All Asp31 substitutions affected enzyme function; D31E, D31Q and D31N reduced activity by 80-90%, and D31A and D31L by > 90%. All D31 mutants had modified kinetics, ranging from three-fold (D31N) to 283-fold (D31L) increases in K(m) for dihydrofolate, and 12-fold (D31N) to 223 077-fold (D31L) decreases in k(cat)/K(m). Of the Leu32 substitutions, only L32D caused reduced enzyme activity (67%) and kinetic differences from the wild type (seven-fold increase in K(m); 21-fold decrease in k(cat)/K(m)). Only minor variations in the K(m) for NADPH were observed for all substitutions. Whereas the L32F mutant retained similar trimethoprim affinity as the wild type, the L32A mutation resulted in a 12-fold decrease in affinity and the L32D mutation resulted in a seven-fold increase in affinity for trimethoprim. These findings support the hypotheses that Asp31 plays a functional role in binding of the substrate and Leu32 plays a functional role in binding of trimethoprim.
authors.affiliation: Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
authors.forename: Ronnie A
authors.initials: RA
authors.lastname: Böck
authors.forename: Jose L
authors.initials: JL
authors.lastname: Soulages
authors.forename: William W
authors.initials: WW
authors.lastname: Barrow
mesh_terms: D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology; D001224:Aspartic Acid / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000737:chemistry*; D004926:Escherichia coli / Q000378:metabolism; D020128:Inhibitory Concentration 50; D007700:Kinetics; D007930:Leucine / Q000737:chemistry; D008954:Models, Biological; D008956:Models, Chemical; D009154:Mutation; D009162:Mycobacterium avium / Q000201:enzymology*; D017433:Protein Structure, Secondary; D013379:Substrate Specificity; D013762:Tetrahydrofolate Dehydrogenase / Q000737:chemistry* / Q000502:physiology*; D014295:Trimethoprim / Q000737:chemistry
chemical_list: D000892:Anti-Infective Agents, Urinary; D004791:Enzyme Inhibitors; D001224:Aspartic Acid; D014295:Trimethoprim; D013762:Tetrahydrofolate Dehydrogenase; D007930:Leucine